The Phase 2 Study of Bardoxolone Methyl in Patients with Chronic Kidney Disease and Type 2 Diabetes (TSUBAKI) aimed to determine if patients without risk factors, including baseline BNP >200 pg/mL or significant cardiovascular histories, can alleviate the fluid overload and heart failure. This evidence concerns the gene NPPB and heart failure.